Provided by Tiger Trade Technology Pte. Ltd.

IMMUNEONCO-B

3.710
0.000
Volume:1.31M
Turnover:5.01M
Market Cap:1.59B
PE:-6.00
High:3.930
Open:3.700
Low:3.700
Close:3.710
52wk High:16.800
52wk Low:2.800
Shares:429.00M
HK Float Shares:418.00M
Volume Ratio:1.41
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.618
ROE:-40.11%
ROA:-16.24%
PB:2.18
PE(LYR):-6.00
PS:10.83

Loading ...

ImmuneOnco Biopharmaceuticals FY2025; revenue rises to CNY 154 million due to Axion payments

Reuters
·
Mar 25

ImmuneOnco Biopharmaceuticals FY2025 operating loss narrows 30.74% to RMB219 million; revenue jumps 108.23% to RMB154 million due to Axion Bio payments

Reuters
·
Mar 25

IMMUNEONCO-B (01541) Completes Enrollment of 133 Patients for Interim Analysis in Phase III Trial of IMM01 (Tidapaxic) as First-Line Treatment for Chronic Myelomonocytic Leukemia

Stock News
·
Mar 23

ImmuneOnco completes enrollment of 133 patients for interim analysis in Phase III IMM01 CMML trial

Reuters
·
Mar 23

IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy

Stock News
·
Mar 18

IMMUNEONCO-B (01541) Schedules 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express
·
Mar 13

ImmuneOnco Biopharmaceuticals schedules board meeting to approve annual results and consider final dividend

Reuters
·
Mar 13

IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval

Stock News
·
Mar 09

ImmuneOnco Biopharmaceuticals Receives Regulatory Nod to Begin Human Trials of IMM0306S

MT Newswires Live
·
Mar 09

BRIEF-ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S

Reuters
·
Mar 07

IMMUNEONCO-B (01541) Reports Unusual Share Price Movements and IND Approval for IMM0306S

Bulletin Express
·
Mar 06

ImmuneOnco Biopharmaceuticals Shanghai - Approval From Nmpa China for Investigational New Drug Application of Imm0306s (Subcutaneous Formulation)

THOMSON REUTERS
·
Mar 06

ImmuneOnco Says It Knows No Cause for Share Price Swings

Reuters
·
Mar 06

IMMUNEONCO-B (01541) Surges Over 16% Following IND Approval for Subcutaneous IMM0306S in Lupus Treatment

Stock News
·
Mar 06

IMMUNEONCO-B (01541) Reports Unchanged Share Capital for February 2026

Bulletin Express
·
Mar 05